17 beta-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16270%2F15%3A43873767" target="_blank" >RIV/62157124:16270/15:43873767 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/15:00083937 RIV/62156489:43210/15:43907650

Výsledek na webu

<a href="http://www.spandidos-publications.com/10.3892/or.2014.3627" target="_blank" >http://www.spandidos-publications.com/10.3892/or.2014.3627</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/or.2014.3627" target="_blank" >10.3892/or.2014.3627</a>

Jazyk výsledku

angličtina

Název v původním jazyce

17 beta-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line

Popis výsledku v původním jazyce

The present study suggests and describes the application of a delivery system for antisense oligonucleotides against mRNA encoding estrogen receptor proteins alpha and beta. The delivery system is composed of a cationic liposome envelope containing 17 beta-estradiol (E-2) in its structure. Cationic liposomes protect cargo against the extracellular matrix, and E-2 can increase its shuttling efficiency into cells. Using MCF-7 cells derived from estrogen receptor-positive ductal carcinoma, treatment with liposomes against ER alpha was found to decrease MCF-7 proliferation, and importantly the application of both the antisense against ER alpha and beta exhibited an antiproliferative effect expressed as cell viability. Using qRT-PCR, it was shown that MTIA,NF-kappa B1 and K-ras genes, but not TFF1, were downregulated using E-2-based liposomes (evaluated at P=0.05). Further indicators of oxidative stress were employed to assess the effect on treatment efficiency. Glutathione (GSH/GSSG redox ratio), metallothionein (MT) and malondialdehyde (MDA) confirmed a positive effect of antisense therapy resulting in their decreased levels in the MCF-7 cells. Based on these data, we suggest that E2-based liposomes offer sufficient transfer efficiency and moreover, due to the effect on NF-kappa BI, MT and GSH, tumor cells can be chemosensitized to increase treatment effectiveness.

Název v anglickém jazyce

17 beta-estradiol-containing liposomes as a novel delivery system for the antisense therapy of ER-positive breast cancer: An in vitro study on the MCF-7 cell line

Popis výsledku anglicky

The present study suggests and describes the application of a delivery system for antisense oligonucleotides against mRNA encoding estrogen receptor proteins alpha and beta. The delivery system is composed of a cationic liposome envelope containing 17 beta-estradiol (E-2) in its structure. Cationic liposomes protect cargo against the extracellular matrix, and E-2 can increase its shuttling efficiency into cells. Using MCF-7 cells derived from estrogen receptor-positive ductal carcinoma, treatment with liposomes against ER alpha was found to decrease MCF-7 proliferation, and importantly the application of both the antisense against ER alpha and beta exhibited an antiproliferative effect expressed as cell viability. Using qRT-PCR, it was shown that MTIA,NF-kappa B1 and K-ras genes, but not TFF1, were downregulated using E-2-based liposomes (evaluated at P=0.05). Further indicators of oxidative stress were employed to assess the effect on treatment efficiency. Glutathione (GSH/GSSG redox ratio), metallothionein (MT) and malondialdehyde (MDA) confirmed a positive effect of antisense therapy resulting in their decreased levels in the MCF-7 cells. Based on these data, we suggest that E2-based liposomes offer sufficient transfer efficiency and moreover, due to the effect on NF-kappa BI, MT and GSH, tumor cells can be chemosensitized to increase treatment effectiveness.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Oncology reports

ISSN

1021-335X

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

9

Strana od-do

921-929

Kód UT WoS článku

000348338500054

EID výsledku v databázi Scopus

—